

Rhabdomyosarcoma and Soft Tissue Sarcoma Pediatric Surveillance & Follow-up Guidelines

ATTACH PATIENT ID

	Months from end of therapy	Date	Location	H&P	CBC	Chem	Imaging of Primary	CXR	Urine tests	GFR	ECHO#	PFTs	LH, FSH, Test or Est	Additional screening	Other	General		
Early Follow-up Clinic	0				End of treatment evaluations (per protocol)											Summary for LTFU clinic		
	3			+	+	+	+	+	+									
	6			+	+		+	+									Attenuated vaccine re-immunizations	
	9			+			+	+										
	12			+	+	+	+	+	+		+						Live vaccine re-immunizations	
	16			+			+	+										
	20			+			+	+										
24			+	+		+	+											
LTFU Clinic	28			+			+	+										
	32			+			+	+										
	36			+	+		+	+										
	42			+			+	+										
	48			+	+		+	+										
	54			+			+	+										
	60			+	+		+	+									Refer to Late Effects clinic	
Notes					Lytes, Ca, Mg, PO4, Cr, urea, LFTs			U/A, urine Prot:Cr & Alb:Cr ratio	If renal RT or injury. Repeat Q2y if abN	#Insert frequency based on cardiac guidelines. ECG if clinical concerns	If lung RT or surgery. Repeat Q2y if abN	Baseline age 11 y if CED \geq 4, pelvic RT or clinical concerns. Rpt Q1y	Based on site of surgery or RT (le ophtho & audiol if H&N RT; endo* testing if CNS RT)					

[^]CED: Cyclophosphamide Equivalence Dose (see over)
^{*}Endo testing: Non-fasting glucose & lipid panel, IGF-1

<p>Further Surveillance</p> <p>Semen Analysis Anti-Mullerian Hormone</p> <p>Breast MRI and Mammogram Colonoscopy or stool tests</p>	<p>From age 18y in males if moderate or high risk From age 12y in females if CED \geq 6 g/m² or pelvic RT; or earlier if clinical concerns. Rpt Q2-3y if normal. Refer to Pediatric Gynecology if abnormal From later of age 25y or 8y after exposure if chest RT From later of age 30y or 5y after exposure to abdominal RT</p>
--	--

Cardiac Surveillance Guidelines (BC)

Anthracycline Dose*	Radiation Dose**	Recommended Frequency of Echo***
<100 mg/m ²	< 15 Gy	No screening
<100 mg/m ²	15 Gy to < 30 Gy	Every 5 years
≥ 100 mg/m ² to <250 mg/m ²	<15 gy	Every 5 years
≥ 100 mg/m ² to <250 mg/m ²	>15 Gy	Every 2 years
Any	> 30 Gy	Every 2 years
≥250 mg/m ²	Any	Every 2 years

*Based on total doses of doxorubicin or the equivalent doses of other anthracyclines

**Based on radiation dose with potential impact to heart (radiation to chest, abdomen, spine [thoracic, whole], total body [TBI]) COG LTFU Guidelines version 6.0 (Oct 2023)

***Consider increased frequency if known high risk genetic variant for anthracycline toxicity

Risk of Prolonged Oligospermia or Azoospermia

Agent	Possible Risk	High Risk
Cyclophosphamide	> 4g/m ²	> 7.5 g/m ²
Busulphan		> 600 mg/m ²
Melphalan		> 140 mg/m ²
Ifosfamide	> 42 g/m ²	> 60 g/m ²
Procarbazine	> 3 g/m ²	> 4 g/m ²
Chlorambucil		> 1.4 g/m ²
BCNU	> 300 mg/m ²	> 1 g/m ²
CCNU		> 500 mg/m ²
Cisplatin	> 300 mg/m ²	> 600 mg/m ²
Testicular RT dose	> 200 cGy	> 1200 cGy

*Lower doses are still possible risk

1. Green J Clin Oncol 2010;28:332-9
2. Meistrich Pediatr Blood Cancer 2009;53:261-6
3. Wync Human Reprod Update 2010;16(3):312-328

Risk of Premature Ovarian Insufficiency or Infertility

Agent	Possible Risk	High Risk	Ref
CED	> 4 g/m ²	> 8 g/m ²	1
Procarbazine	> 2 g/m ²	> 4 g/m ²	2
Cisplatin	> 300 mg/m ²		3
Dactinomycin	>12.2 mg/m ²		4
Ovarian RT dose*	> 100 cGy	> 1000 cGy	5

*Age dependent (see nomogram⁵)

^Bevacizumab can cause ovarian failure; possibly acute and transient only⁶

1. Green Pediatr Blood Cancer 2014;61(1):53-67
2. Van der Kaaij J Clin Oncol 2012;30(3):291-299
3. Solheim Gyne Oncol 2015;136(2):224-229
4. Van Den Berg Hum Reprod 2018; 33(8):1474-1488
5. Wallace Int J Radiat Oncol;62(3):738-744
6. Imai Molec Clin Oncol 2017;6:807-810

Anthracycline Equivalent Dose

Agent	Correction factor
Doxorubicin	1.0
Daunorubicin	0.5
Epirubicin	0.67
Mitoxantrone	10.0
Idarubicin	5.0

COG LTFU Guidelines version 6.0 (Oct 2023)

Cyclophosphamide Equivalent Dose (CED)

Agent	Correction factor
Cyclophosphamide	1.0
Ifosfamide	0.244
Procarbazine	0.857
Chlorambucil	14.286
BCNU	15
CCNU	16
Melphalan	40
Thiotepa	50
Nitrogen Mustard	100
Busulphan	8.823

Green Pediatr Blood Ca 2014;61:53-67